ライフサイエンスコーパス: rhinitis

1 wn risk factors for asthma, such as allergic rhinitis).

2 1.28; 95% CI 1.04-1.58) were associated with rhinitis.

3 includes food allergy, asthma, and allergic rhinitis.

4 ma, aeroallergen sensitization, and allergic rhinitis.

5 notherapy are effective in seasonal allergic rhinitis.

6 l immunotherapy in the treatment of allergic rhinitis.

7 arent reduction in the incidence of allergic rhinitis.

8 levels at any time point with ever allergic rhinitis.

9 o-called idiopathic (previously 'vasomotor') rhinitis.

10 equent wheeze/asthma, eczema and/or allergic rhinitis.

11 e either unique or common to both asthma and rhinitis.

12 sthma to argan powder and a probable case of rhinitis.

13 lustrate key concepts of the pathogenesis of rhinitis.

14 ave beneficial effects on childhood allergic rhinitis.

15 ated with reduced allergic sensitization and rhinitis.

16 icacious in treating HDM-associated allergic rhinitis.

17 was only positively associated with allergic rhinitis.

18 subcutaneous and sublingual immunotherapy in rhinitis.

19 lects the real-life epidemiology of allergic rhinitis.

20 vident for allergic phenotypes of asthma and rhinitis.

21 t, and more severe and commonly intermittent rhinitis.

22 nation pharmacotherapy for seasonal allergic rhinitis.

23 ts with moderate to severe seasonal allergic rhinitis, 2 years of sublingual grass pollen immunothera

24 Most common comorbidities were allergic rhinitis (62.4%), gastroesophageal reflux (42.1%), sinus

25 The most frequent comorbidities were rhinitis (84.0%), sinusitis (47.8%), and gastroesophagea

26 Seasonal allergens were associated with rhinitis, a longer time to asthma development, and more

27 u c 1 with M/S-R and Equ c 3 with persistent rhinitis, AD and severe asthma.

28 was associated with reduced odds of allergic rhinitis (adjusted odds ratio, 0.35; 95% CI, 0.19-0.64;

29 ssociated with increased odds of nonallergic rhinitis (adjusted odds ratio, 1.43; 95% CI, 1.06-1.93;

30 , -1.55 to -0.06]; P = 0.0348), and allergic rhinitis (adjusted odds ratio, 4.83 [95% CI, 1.58-14.78]

31 Allergic rhinitis affects approximately one in four of the popula

32 therapy (AIT) for the management of allergic rhinitis, allergic asthma, IgE-mediated food allergy and

33 c conditions (food allergy, asthma, allergic rhinitis, allergic conjunctivitis, and eosinophilic esop

34 Non-allergic rhinitis also is a risk factor for the development of as

35 iation of serum cotinine levels with current rhinitis among children without allergic sensitization (

36 ars to be associated with childhood allergic rhinitis and aeroallergen sensitization, the effect dire

37 The number of genes related to allergic rhinitis and allergic asthma increases steadily; however

38 se dust mite and is associated with allergic rhinitis and allergic asthma.

39 e-modifying treatment available for allergic rhinitis and allergic asthma.

40 tain its association with childhood allergic rhinitis and allergic sensitization.

41 inding was mirrored by relationships between rhinitis and antibody responses to grass.

42 was well tolerated in patients with allergic rhinitis and appears to reduce allergic responses clinic

43 Allergic rhinitis and asthma constitute two clinical expressions

44 istics and treatment over a 1-year period of rhinitis and asthma multimorbidity at baseline (cross-se

45 The phenotypic characteristics of rhinitis and asthma multimorbidity in adults and the eld

46 Allergy Diary and CARAT: Control of Allergic Rhinitis and Asthma Test) in 22 Reference Sites or regio

47 ic diseases, including respiratory (allergic rhinitis and asthma) and skin (atopic dermatitis and ecz

48 It is widely believed that for allergic rhinitis and asthma, avoidance of specific triggers can

49 tive in patients with IgE-dependent allergic rhinitis and asthma.

50 been demonstrated in patients with allergic rhinitis and asthma.

51 iOS and Android) to have tested for allergic rhinitis and conjunctivitis.

52 HDM-allergic patients who suffered from rhinitis and eczema showed a significant decrease in IgA

53 associated with increased risks of allergic rhinitis and eczema up to 18 years, and sensitization an

54 gy avoidance resulted in reduced symptoms of rhinitis and improved QoL.

55 -IS Question 9) are similar in users without rhinitis and in those with mild rhinitis (scores 0-2).

56 d Asthma European Network (Ga2len), Allergic Rhinitis and Its Impact on Asthma (ARIA), and the Respir

57 gies in rhinitis control, the ARIA (Allergic Rhinitis and its Impact on Asthma) score ranging from 0

58 he effect is mainly confined to non-allergic rhinitis and more pronounced in adolescents than in youn

59 We report that otitis media, rhinitis and nasopharyngitis occur at high frequency in

60 t study, 18 subjects with perennial allergic rhinitis and sensitization to HDM were exposed to HDM al

61 rs and the subsequent development of asthma, rhinitis and sensitization to inhalant allergens between

62 m 15 allergic individuals with asthma and/or rhinitis and sensitized to mosquito.

63 childhood wheeze/asthma, eczema and allergic rhinitis and young adult asthma.

64 dult patients with a first-time diagnosis of rhinitis and/or asthma.

65 Around 50% of users with troublesome rhinitis and/or ocular symptoms suffered work impairment

66 Asthma, hay fever (or allergic rhinitis) and eczema (or atopic dermatitis) often coexis

67 n-3 and n-6 PUFAs at age 8 years and asthma, rhinitis, and aeroallergen sensitization at age 16 years

68 ted with a reduced risk of prevalent asthma, rhinitis, and aeroallergen sensitization at age 16 years

69 confounders on the prevalence of asthma and rhinitis, and allergic multimorbidity in each cohort sep

70 HDM were associated with more common rhinitis, and Alternaria was associated with asthma.

71 MeDALL showed the multimorbidity of eczema, rhinitis, and asthma and estimated that only 38% of mult

72 opic dermatitis (AD), food allergy, allergic rhinitis, and asthma are common atopic disorders of comp

73 Atopic conditions (atopic dermatitis, rhinitis, and asthma) belong to the most common noncommu

74 arize the current knowledge on major asthma, rhinitis, and atopic dermatitis endotypes under the ausp

75 road relevance for the management of asthma, rhinitis, and atopic dermatitis in the context of a bett

76 roach for non-type 2 immune response asthma, rhinitis, and atopic dermatitis is lagging behind.

77 s atopic diseases including asthma, allergic rhinitis, and atopic dermatitis.

78 d measures of asthma (10, 18 years), eczema, rhinitis, and atopy (1-or-2, 4, 10, 18 years) risks was

79 , clinical mechanisms, allergens, asthma and rhinitis, and clinical allergy are all covered.

80 Asthma, rhinitis, and eczema are complex diseases with multiple

81 evels and allergic disease (allergic asthma, rhinitis, and eczema) and between alcohol consumption an

82 rns were investigated in relation to asthma, rhinitis, and eczema.

83 ns associate with the development of asthma, rhinitis, and eczema.

84 h2 cells from subjects with allergic asthma, rhinitis, and healthy controls.

85 dinal associations between prevalent asthma, rhinitis, and IgE sensitization and mold or dampness ind

86 Odds ratios for eczema, asthma, rhinitis, and multimorbidity in relation to sensitizatio

87 tivity (BHR), flexural eczema (FE), allergic rhinitis, and sensitization in childhood and early adult

88 the upper airways of allergic patients with rhinitis, and their association with key type 2 mediator

89 idence interval [CI]: 1.15-7.60) and current rhinitis (AOR = 2.71; 95% CI: 1.07-6.89), while the asso

90 (AOR = 3.34; 95% CI: 1.05-10.61) and current rhinitis (AOR = 4.23; 95% CI: 1.28-13.97) among adolesce

91 s (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) assesses allergic rhinitis

92 s (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) app (Allergy Diary) on smartphones screens to

93 hile the association for physician-diagnosed rhinitis approaching borderline significance (AOR = 2.26

94 In users with uncontrolled rhinitis, approximately 90% had some work impairment and

95 Allergic rhinitis (AR) and asthma are common allergic conditions

96 ting adult treatment algorithms for allergic rhinitis (AR) and chronic rhinosinusitis (CRS).

97 Baseline allergic rhinitis (AR) and peanut SPT wheal size were significant

98 apy (AIT) is the only treatment for allergic rhinitis (AR) and/or allergic asthma (AA) with long-term

99 Asthma and allergic rhinitis (AR) are common allergic comorbidities with a s

100 f pharmacotherapy for patients with allergic rhinitis (AR) depends on several factors, including age,

101 decreased probability of having an allergic rhinitis (AR) exacerbation day (from 11% [placebo] to 5%

102 Allergic rhinitis (AR) is characterized by mucosal inflammation,

103 ch on medical care and treatment of allergic rhinitis (AR) is scarce.

104 he first step in the development of allergic rhinitis (AR) or an independent phenotype.

105 Diagnoses of current allergic rhinitis (AR) related to mite allergy and asthma were ba

106 challenge (NAC) is a human model of allergic rhinitis (AR) that delivers standardized allergens local

107 between periodontitis and previous allergic rhinitis (AR) using a matched patient-control study desi

108 Allergic rhinitis (AR) was defined as one or more positive result

109 delines on the treatment of asthma, allergic rhinitis (AR), and allergen immunotherapy (AIT) lack rec

110 Allergic rhinitis (AR), chronic rhinosinusitis (CRS) and asthma o

111 airment of quality of life (QoL) in allergic rhinitis (AR), the degree of impairment in QoL in nonall

112 ite the socioeconomic importance of allergic rhinitis (AR), very few prospective studies have been pe

113 peutic targets and/or biomarkers of allergic rhinitis (AR).

114 pray/nostril bid), in children with allergic rhinitis (AR).

115 inflammation seen in patients with allergic rhinitis (AR).

116 with moderate-to-severe HDM-induced allergic rhinitis (AR).

117 iagnose and characterize asthma and allergic rhinitis (AR).

118 TJs remain unknown in patients with allergic rhinitis (AR).

119 Epidemiology, clinical allergy, asthma and rhinitis are all covered.

120 associated with the pathogenesis of allergic rhinitis are not entirely clear.

121 Although most children with asthma and rhinitis are sensitized to aeroallergens, only a minorit

122 Whilst many children with asthma or rhinitis are sensitized to airborne allergens, primary c

123 Allergic asthma and rhinitis are two common chronic allergic diseases that a

124 ated to the treatment of asthma and allergic rhinitis as primary outcomes.

125 ed the sex-specific prevalence of asthma and rhinitis as single and as multimorbid diseases before an

126 impact on work productivity of uncontrolled rhinitis assessed by visual analogue scale (VAS).

127 m four recent systematic reviews on allergic rhinitis, asthma, food allergy and venom allergy, respec

128 th strong associations observed for allergic rhinitis at 12 (OR = 5.69[95% CI: 1.83,17.60] per weight

129 OR 3.45, 95% CI 1.07-11.74), as was allergic rhinitis at 5-7 years of age (adjusted OR 4.06, 95% CI 1

130 ffer was positively associated with allergic rhinitis at 6-8 years in BAMSE (odds ratio = 1.42, 95% c

131 f food allergy, asthma, eczema, and allergic rhinitis at age 4 years.

132 th 21% and 20% reduced odds of ever allergic rhinitis at school age (odds ratios of 0.79 [95% CI, 0.6

133 Allergic rhinitis, atopic eczema and food hypersensitivity were c

134 For allergic rhinitis, authors focused on the prediction of and effec

135 s in symptoms of gastroesophageal reflux and rhinitis, bronchial reversibility, and exhaled nitric ox

136 d with inflammatory responses as in allergic rhinitis but can also occur in the absence of inflammati

137 s defined as clinically relevant symptoms of rhinitis but without positive results on skin prick test

138 Infective rhinitis can be caused by viruses, and less commonly by

139 was significantly associated with persistent rhinitis, Can f 2 with asthma diagnosis, Can f 3 with mo

140 asthma-related comorbidities are discussed: rhinitis, chronic rhinosinusitis, gastroesophageal reflu

141 er, presence of symptoms of asthma, allergic rhinitis, chronic rhinosinusitis, smoking status, and hi

142 ge of the 4q35 region to asthma and allergic rhinitis comorbidity (AAR; P = 7.2 x 10(-5)).

143 special reference to allergen-related asthma-rhinitis comorbidity.

144 t in multimorbid patients who had asthma and rhinitis concurrently.

145 Allergy was defined as reported rhinitis, conjunctivitis, or asthma at exposure to cat o

146 We compared three tools-the Rhinitis Control Assessment Test (RCAT), Rhinoconjunctiv

147 echnology has been used to appraise allergic rhinitis control, but more data are needed.

148 ess the importance of mobile technologies in rhinitis control, the ARIA (Allergic Rhinitis and its Im

149 of MeDALL, we assessed the outcomes: current rhinitis, current asthma, current allergic multimorbidit

150 , which was defined as the rhinitis DSS plus rhinitis daily medication score (DMS), during the last 8

151 A rhinitis daily symptom score (DSS; 4 nasal symptoms, max

152 s were less than .001 versus placebo, except rhinitis DMS (P = 0.15).

153 econdary end points of average rhinitis DSS, rhinitis DMS, total combined rhinoconjunctivitis score,

154 , a large majority of subjects with allergic rhinitis do not develop asthma, suggesting divergence in

155 ned rhinitis score, which was defined as the rhinitis DSS plus rhinitis daily medication score (DMS),

156 acebo in the secondary end points of average rhinitis DSS, rhinitis DMS, total combined rhinoconjunct

157 ect development of allergic sensitization or rhinitis during childhood questioning the relevance of a

158 osure in perinatal life and sensitization or rhinitis during childhood.

159 frequently reported symptoms were urticaria, rhinitis, dyspnoea and cough.

160 life was evaluated with validated scales for rhinitis (ESPRINT-15) and asthma (Mini-AQLQ).

161 inine levels were positively associated with rhinitis ever (adjusted odds ratio [AOR] = 2.95; 95% con

162 inine levels were positively associated with rhinitis ever (AOR = 3.34; 95% CI: 1.05-10.61) and curre

163 Symptoms of wheeze, rhinitis, fever, and environmental exposures were docume

164 and management of allergic and non-allergic rhinitis, first published in 2007.

165 ic children and susceptibility to asthma and rhinitis, focusing on responses to house dust mite and g

166 Most allergic diseases, such as asthma, rhinitis, food allergies, and atopic dermatitis, are gen

167 comes and Measures: Wheeze, eczema, allergic rhinitis, food allergy, allergic sensitization, type 1 d

168 children were assessed for asthma, allergic rhinitis, food allergy, and atopic dermatitis.

169 notypic differences between a priori defined rhinitis groups.

170 therapy tablets in the treatment of allergic rhinitis has been firmly established in large multicente

171 Sublingual immunotherapy for allergic rhinitis has been used successfully for years in Europe,

172 between tobacco smoke exposure and childhood rhinitis has not been established in developed or develo

173 evaluating the relation between obesity and rhinitis have yielded conflicting results.

174 ssociation between serum cotinine levels and rhinitis in a population sample of 1,315 Asian children.

175 d Google Trends terms related to allergy and rhinitis in all European Union countries, Norway and Swi

176 assess the relationship between obesity and rhinitis in children and adults.

177 atitis during infancy to asthma and allergic rhinitis in later childhood.

178 e olfactory bulb (OB), we induced persistent rhinitis in mice and analyzed the spatial and temporal p

179 pharmacologic treatment of seasonal allergic rhinitis in patients aged 12 years or older.

180 : For initial treatment of seasonal allergic rhinitis in persons aged 12 years or older, routinely pr

181 ment of moderate to severe seasonal allergic rhinitis in persons aged 12 years or older, the clinicia

182 : For initial treatment of seasonal allergic rhinitis in persons aged 15 years or older, recommend an

183 Amongst children with known asthma and/or rhinitis in primary care, taking a structured allergy hi

184 etermine the prevalence and impact of QOL of rhinitis in swimming compared to nonswimming athletes an

185 sment of burden, diagnosis and management of rhinitis in the elderly by comparison with an adult popu

186 ides a new option for patients with allergic rhinitis in the United States.

187 indoor allergens causing allergic asthma and rhinitis in tropical and subtropical regions.

188 hether having pollinosis (a form of allergic rhinitis) in a follow-up survey could predict all-cause

189 ts with moderate to severe seasonal allergic rhinitis (interfering with usual daily activities or sle

190 uster C had minimally symptomatic asthma and rhinitis, intermediate allergy and inflammation, and mil

191 saicin treatment in patients with idiopathic rhinitis (IR) is based on ablation of the transient rece

192 y of capsaicin nasal treatment in idiopathic rhinitis (IR).

193 Rhinitis is a heterogeneous condition that has been asso

194 Treatment of rhinitis is associated with benefits for asthma.

195 Allergic rhinitis is common and affects 10-15% of children and 26

196 Allergic rhinitis is diagnosed by history and examination, suppor

197 The prevalence of allergic rhinitis is high, but the role of environmental factors

198 lergen immunotherapy (AIT) on local allergic rhinitis (LAR) are largely unknown.

199 about the natural history of local allergic rhinitis (LAR) is limited.

200 efined a new phenotype called local allergic rhinitis (LAR) or 'entopy'.

201 be an effective treatment for local allergic rhinitis (LAR) to house dust mites.

202 thma diagnosis, Can f 3 with moderate/severe rhinitis (M/S-R) and asthma diagnosis (AD), and Can f 5

203 The MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhin

204 y was to validate the use of VAS in the MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhin

205 Non-allergic rhinitis may be a presenting complaint for systemic diso

206 ed in patients with both asthma and allergic rhinitis, may be cost-effective with an incremental cost

207 The probability of having had allergic rhinitis medication prescribed was also reduced in the f

208 was no association between KCN and allergic rhinitis, mitral valve disorder, aortic aneurysm, or dep

209 "Mixed rhinitis" (MR) patients have more than one major etiolog

210 atients suffering from IgE-mediated allergic rhinitis (n=10) and healthy controls (n=10).

211 Participants with allergic rhinitis (n=42) were randomized to receive eight weekly

212 ential diagnosis between LAR and nonallergic rhinitis (NAR) has become a challenge for the clinician.

213 e degree of impairment in QoL in nonallergic rhinitis (NAR) remained unknown for a long time, due to

214 Nonallergic rhinitis (NAR) was defined as clinically relevant sympto

215 The prevalence of nonallergic rhinitis (NAR) was significantly higher in elite swimmer

216 ed the cost-effectiveness of AIT in allergic rhinitis, of which seven were based on data from randomi

217 Allergic rhinitis often impairs social life and performance.

218 Current rhinitis only affected girls less often than boys before

219 evels compared to patients who suffered from rhinitis only.

220 were observed between TAC and development of rhinitis or asthma, although a significant inverse assoc

221 protection against long-term asthma, eczema, rhinitis or atopy.

222 ergic asthma (OR 1.80; 95% CI 1.27-2.55) and rhinitis (OR 1.41; 95% CI 1.03-1.93).

223 ve been recognized as causes of occupational rhinitis (OR).

224 opic march from early AD to asthma, allergic rhinitis, or both later in life and the extensive comorb

225 during infancy increases the risk of asthma, rhinitis, or IgE sensitization in children followed from

226 Perennial allergic rhinitis (PAR) represents a global and public health pro

227 In PBMCs of allergic rhinitis participants, 42 sites showed significant DNA m

228 ssociated with increased odds of nonallergic rhinitis, particularly in male subjects.

229 ontrol subjects, AR patients, and idiopathic rhinitis patients and were tested in vitro.

230 as nasal secretions of AR but not idiopathic rhinitis patients rapidly decreased epithelial barrier i

231 validated tool to assess control in allergic rhinitis patients.

232 inear dose response (all: R(2) > 0.98) in 33 rhinitis patients.

233 spiratory allergy, i.e., asthma and allergic rhinitis, plaguing westernized countries, with up to 8%

234 (pooled OR 2.7; 95% CI 1.7-4.4) and allergic rhinitis (pooled OR 3.1; 95% CI 1.9-4.9) from 4 to 8 yea

235 rovides second line treatment for those with rhinitis poorly controlled on monotherapy.

236 Allergic rhinitis prevalence was similar in all groups (12%-18%).

237 ic multimorbidity (ie, concurrent asthma and rhinitis), puberty status and allergic sensitization by

238 rial, 37 participants with seasonal allergic rhinitis received suboptimal SCIT (30,000 standardized q

239 testing and clinically relevant symptoms of rhinitis related to their sensitization.

240 with an increased probability of asthma and rhinitis remission between 8 and 16 years of age.

241 upports the interpretation that persons with rhinitis report both the presence and the absence of sym

242 ing for >4 months protected against repeated rhinitis (RR = 0.36, 95% CI = 0.18-0.71, P = 0.003).

243 Seasonal allergic rhinitis (SAR) caused by intermittent exposure to season

244 us research, patients with seasonal allergic rhinitis (SAR) showed poorer school and work performance

245 The primary end point was the total combined rhinitis score (ie, the sum of rhinitis symptom and medi

246 t with 12 SQ-HDM improved the total combined rhinitis score by 17% (95% CI, 10% to 25%) versus placeb

247 ary end point was the average total combined rhinitis score, which was defined as the rhinitis DSS pl

248 sers without rhinitis and in those with mild rhinitis (scores 0-2).

249 etween vitamin D exposure with ever allergic rhinitis, serum total IgE level, and allergen sensitizat

250 gan-specific symptoms, medication-free days, rhinitis severity and asthma control.

251 Markers of rhinitis severity and atopy were among the other major d

252 n addition to pulmonary physiology measures, rhinitis severity and atopy were associated with high-do

253 rgic inflammation, pulmonary physiology, and rhinitis severity domains to asthma severity) and the ET

254 Among the domains, pulmonary physiology and rhinitis severity had the largest significant standardiz

255 re distinguished by indicators of asthma and rhinitis severity, pulmonary physiology, allergy (sensit

256 a suggest that swimmers might be affected by rhinitis significantly more often than the general popul

257 otal combined rhinitis score (ie, the sum of rhinitis symptom and medication scores) during the effic

258 receiving the allergy intervention had fewer rhinitis symptoms (MD - 3.14, 95% CI - 6.01, - 0.81) and

259 E exhibited progressively higher asthma and rhinitis symptoms and allergy/inflammation.

260 on smartphones screens to evaluate allergic rhinitis symptoms and disease control.

261 onses in some patients with typical allergic rhinitis symptoms but without atopy and have defined a n

262 Participants recorded their rhinitis symptoms during 4-hour HDM EEC challenges at ra

263 was well tolerated and improved HDM-induced rhinitis symptoms in adults and adolescents.

264 nitis) App (Allergy Diary) assesses allergic rhinitis symptoms, disease control and impact on patient

265 Key secondary end points were rhinitis symptoms, medication scores, quality of life, a

266 concepts and research questions in allergic rhinitis that may not be identified using classical meth

267 The risk factors for asthma (e.g., allergic rhinitis) that were identified either by NLP or the abst

268 he preventive effect on the progression from rhinitis to asthma.

269 93 adults with grass pollen-induced allergic rhinitis to receive 7 preseasonal intradermal allergen i

270 n associated with symptoms ranging from mild rhinitis to severe asthma.

271 The Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy (G

272 treatment in the area under the curve of the rhinitis total symptom score (ChBLAUCRTSS 0-4h).

273 tis Quality of Life Questionnaire (RQLQ) and Rhinitis Total Symptom Score (RTSS)-to determine whether

274 al development programs of selected allergic rhinitis treatments were evaluated.

275 ing infancy increased the risk of asthma and rhinitis up to 16 years of age, particularly for nonalle

276 vitis, drug allergies, eczema, food allergy, rhinitis, urticaria, venom allergy and other probable al

277 ss-sectional study of obesity indicators and rhinitis using data from 8165 participants in the 2005-2

278 allergen challenge in subjects with allergic rhinitis using novel noninvasive methodology.

279 The MASK-rhinitis VAS is a reliable and valid tool to assess alle

280 , sensitivity, and acceptability of the MASK-Rhinitis VAS.

281 Classification of asthma and rhinitis was based on questionnaires, and serum IgE anti

282 Nonallergic rhinitis was defined as a physician's diagnosis and symp

283 Allergic rhinitis was defined as physician-diagnosed hay fever or

284 Parental history of asthma, eczema, or rhinitis was defined by self-reported physician diagnosi

285 Rhinitis was diagnosed at 7 and 13 years.

286 in question used to assess the prevalence of rhinitis was from the ISAAC study.

287 Rhinitis was reported significantly more often by the el

288 Data on asthma, eczema, and allergic rhinitis were captured by validated International Study

289 Symptoms of allergic rhinitis were controlled (VAS-global <20) in approximate

290 Asthma and allergic rhinitis were diagnosed based on predefined algorithms a

291 d study, adults with HDM-associated allergic rhinitis were given a daily sublingual tablet containing

292 Patients with symptoms of rhinitis were recruited from a tertiary care outpatient

293 e association of tobacco smoke exposure with rhinitis, while the effect is mainly confined to non-all

294 y be cost-effective for people with allergic rhinitis with or without asthma and in high-risk subgrou

295 ult patients (19-61 years old) with allergic rhinitis with or without asthma caused by grass pollen w

296 American subjects with HDM-induced allergic rhinitis with or without conjunctivitis (AR/C).

297 n 1 (odds ratio [OR], 3.3; 95% CI, 1.5-7.2), rhinitis with patterns 1 to 4 and 6 (OR, 2.2-4.3), and e

298 d with different allergic clinical pictures (rhinitis with/without asthma), different clinical sympto

299 was significantly different in patients with rhinitis with/without asthma.

300 ant and clinically relevant worsening of the rhinitis, with increase in emergency assistance, develop